<DOC>
	<DOCNO>NCT00777335</DOCNO>
	<brief_summary>The purpose study assess benefit panobinostat monotherapy give either orally i.v . woman HER2-positive locally recurrent metastatic breast cancer</brief_summary>
	<brief_title>Study Panobinostat Monotherapy Women With v-ERB-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 2 ( HER2 ) Positive Locally Recurrent Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Panobinostat</mesh_term>
	<criteria>Written inform consent obtain prior studyrelated procedure Women ≥ 18 year old Patients ECOG performance status ≤ 2 assess within 2 week prior randomization Histologically cytologically confirm invasive breast carcinoma locally recurrent radiological evidence metastatic disease . Locally recurrent disease must amenable resection curative intent . Measurable disease per Response Evaluation Criteria Solid Tumors ( RECIST ) guideline HER2positive breast cancer patient local laboratory test Prior trastuzumabcontaining regimen ( neoadjuvant and/or adjuvant and/or metastatic setting ) regardless whether trastuzumab give monotherapy combination chemotherapy . Any number prior trastuzumab regimen acceptable . Additional treatment lapatinib trastuzumab treatment permit , mandatory . Radiological evidence relapse disease progression trastuzumab ( lapatinib ) within 12 month last dose adjuvant trastuzumab . Complete radiology tumor assessment within 4 week prior randomization : Chest : Computed Tomography ( CT ) scan intravenous contrast contrast medically contraindicate Magnetic Resonance Imaging ( MRI ) Abdomen : CT scan intravenous oral contrast contrast medically contraindicate MRI Brain : CT scan MRI Bone : Whole body Bone Scintigraphy Up 2 prior cytotoxic chemotherapy regimen , addition neoadjuvant adjuvant , treatment metastatic locally recurrent breast cancer ( include cytotoxic chemotherapy treatment combination trastuzumab and/or lapatinib ) Patients must meet follow laboratory criterion within 2 week ( 14 day ) prior randomization : Hematology Neutrophil count &gt; 1200/mm3 Platelet count &gt; 100,000/mm3 Hemoglobin ≥ 90 g/L Biochemistry Aspartate aminotransferase/glutamic oxaloacetic transaminase ( AST/SGOT ) alanine aminotransferase/glutamic pyruvic transaminase ( ALT/SGPT ) ≤ 2.5 x upper limit normal ( ULN ) ≤ 5.0 x ULN transaminase elevation due disease involvement Serum bilirubin ≤ 1.5 x ULN Serum creatinine ≤ 1.5 x ULN 24hour creatinine clearance ≥ 50 mL/min Serum potassium , sodium , magnesium , phosphorus , total calcium ( correct serum albumin ) ionize calcium within normal limit institution Serum albumin ≥ Lower Limit Normal ( LLN ) 30g/L Clinically euthyroid function ( thyroidstimulating hormone ( TSH ) free T4 ) . ( Patients permit receive thyroid hormone supplement treat underlying hypothyroidism ) . Left Ventricular Ejection Fraction ( LVEF ) assessment ( 2D echocardiogram Multiple Uptake Gated Acquisition Scan ( MUGA ) scan ) perform within 6 week prior randomization , show LVEF value &gt; 50 % Electrocardiogram perform within 1 week prior randomization ( detail finding Electrocardiogram acceptable participating study report Exclusion criterion section ) Women childbearing potential ( WOCBP ) must negative serum pregnancy test within 7 day prior randomization agree appropriate method pregnancy prevention Prior Histone Deacetylase ( HDAC ) , Deacetylase ( DAC ) , Heat Shock Protein 90 ( HSP90 ) inhibitor valproic acid treatment cancer Patients need valproic acid medical condition study within 5 day prior first panobinostat treatment Patients receive prior chemotherapy investigational agent within last 4 week prior randomization ( 6 week nitrosoureas mitomycin ; 2 week capecitabine ) Patients receive prior radiotherapy ≥ 25 % bone marrow within last 4 week prior randomization ; local radiotherapy allow however recently irradiate lesion include measurable disease assessment Patients receive prior investigational agent within last 4 week prior randomization Patients unresolved diarrhea ≥CTCAE ( National Cancer Institute Common Terminology Criteria Adverse Events ) grade 1 Impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption oral panobinostat History cardiac dysfunction include one following : Complete leave bundle branch block necessity permanent cardiac pacemaker congenital long QT syndrome history presence ventricular tachyarrhythmias clinically significant rest bradycardia ( &lt; 50 beat per minute ) QTcF &gt; 450 msec screen electrocardiogram ( ECG ) right bundle branch block leave anterior hemiblock ( bifascicular block ) Presence unstable atrial fibrillation ( ventricular response rate &gt; 100 bpm ) . Patients stable atrial fibrillation allow study provide meet cardiac exclusion criterion Previous history angina pectoris acute myocardial infarction ( MI ) within 6 month randomization Congestive heart failure ( New York Heart Association functional classification IIIIV ) Other clinically significant heart disease ( e.g . cardiomyopathy , cardiac artery disease , uncontrolled hypertension , history poor compliance antihypertensive regimen ) Acute chronic liver renal disease Other concurrent severe and/or uncontrolled medical condition ( e.g. , uncontrolled diabetes mellitus , active untreated uncontrolled infection , chronic obstructive chronic restrictive pulmonary disease include dyspnoea rest cause ) could cause unacceptable safety risk compromise compliance protocol Concomitant use drug risk cause torsades de pointes treatment discontinue switched different medication prior start study drug Brain metastasis , unless patient randomize study least 90 day completion brain radiotherapy / surgery without radiologic functional evidence progressive brain metastasis , corticosteroid dose 7.5 mg prednisone equivalent ; No concurrent radiotherapy brain metastasis allow Clinically significant third space fluid accumulation Concurrent bisphosphonates unless initiate prior study entry ( least 4 week study randomization ) Pregnant ( i.e. , positive betahuman chorionic gonadotropin test ) breast feed Unable swallow oral medication Not willing use double barrier method nonhormonal birth control . Contraception must use study 90 day last dose study treatment . Patients significant history noncompliance medical regimen inability grant reliable informed consent</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>